JP6747985B2 - ＴＮＦＲ：Ｆｃ融合タンパク質の精製方法 - Google Patents
ＴＮＦＲ：Ｆｃ融合タンパク質の精製方法 Download PDFInfo
- Publication number
- JP6747985B2 JP6747985B2 JP2016572703A JP2016572703A JP6747985B2 JP 6747985 B2 JP6747985 B2 JP 6747985B2 JP 2016572703 A JP2016572703 A JP 2016572703A JP 2016572703 A JP2016572703 A JP 2016572703A JP 6747985 B2 JP6747985 B2 JP 6747985B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- tnfr
- fusion protein
- column
- hcp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title claims description 127
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title claims description 127
- 108091006020 Fc-tagged proteins Proteins 0.000 title claims description 116
- 238000000034 method Methods 0.000 title claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 263
- 108090000623 proteins and genes Proteins 0.000 claims description 263
- 239000000203 mixture Substances 0.000 claims description 139
- 239000012535 impurity Substances 0.000 claims description 73
- 108091005804 Peptidases Proteins 0.000 claims description 70
- 102000035195 Peptidases Human genes 0.000 claims description 68
- 238000012434 mixed-mode chromatography Methods 0.000 claims description 67
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 50
- 239000000872 buffer Substances 0.000 claims description 46
- 238000001042 affinity chromatography Methods 0.000 claims description 38
- 239000011534 wash buffer Substances 0.000 claims description 32
- 238000000746 purification Methods 0.000 claims description 28
- 108010008165 Etanercept Proteins 0.000 claims description 26
- 229960000403 etanercept Drugs 0.000 claims description 26
- 239000004365 Protease Substances 0.000 claims description 25
- 238000005571 anion exchange chromatography Methods 0.000 claims description 22
- 239000012149 elution buffer Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 12
- 238000007804 gelatin zymography Methods 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 4
- 230000002797 proteolythic effect Effects 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 238000004140 cleaning Methods 0.000 claims 1
- 239000006167 equilibration buffer Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000012561 harvest cell culture fluid Substances 0.000 description 24
- 238000004587 chromatography analysis Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 239000003446 ligand Substances 0.000 description 18
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 15
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 238000011068 loading method Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 12
- 238000005349 anion exchange Methods 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 102000013382 Gelatinases Human genes 0.000 description 9
- 108010026132 Gelatinases Proteins 0.000 description 9
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 239000012145 high-salt buffer Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000011026 diafiltration Methods 0.000 description 7
- 238000004255 ion exchange chromatography Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 238000011210 chromatographic step Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091008038 CHOP Proteins 0.000 description 5
- 102100021246 DDIT3 upstream open reading frame protein Human genes 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 239000012515 MabSelect SuRe Substances 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 3
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 description 3
- LYUQWQRTDLVQGA-UHFFFAOYSA-N 3-phenylpropylamine Chemical compound NCCCC1=CC=CC=C1 LYUQWQRTDLVQGA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000012539 chromatography resin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012562 protein A resin Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013019 capto adhere Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YUWAUUTYKFAJBH-UHFFFAOYSA-N pyridin-4-ylmethanethiol Chemical compound SCC1=CC=NC=C1 YUWAUUTYKFAJBH-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000011100 viral filtration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 239000012549 Fractogel® EMD DEAE (M) Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 238000012855 HCP-ELISA Methods 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013018 capto adhere resin Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- -1 veratacept Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/203—Equilibration or regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1919/MUM/2014 | 2014-06-13 | ||
| IN1919MU2014 | 2014-06-13 | ||
| PCT/IB2015/054494 WO2015189832A1 (en) | 2014-06-13 | 2015-06-13 | Process for the purification of tnfr:fc fusion protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521389A JP2017521389A (ja) | 2017-08-03 |
| JP2017521389A5 JP2017521389A5 (OSRAM) | 2018-07-19 |
| JP6747985B2 true JP6747985B2 (ja) | 2020-08-26 |
Family
ID=53524922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572703A Expired - Fee Related JP6747985B2 (ja) | 2014-06-13 | 2015-06-13 | ＴＮＦＲ：Ｆｃ融合タンパク質の精製方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10556942B2 (OSRAM) |
| EP (1) | EP3155009A1 (OSRAM) |
| JP (1) | JP6747985B2 (OSRAM) |
| CN (1) | CN106536565A (OSRAM) |
| AU (1) | AU2015273049B2 (OSRAM) |
| BR (1) | BR112016029157A8 (OSRAM) |
| CA (1) | CA2951766A1 (OSRAM) |
| MA (1) | MA40232A (OSRAM) |
| MX (1) | MX2016016318A (OSRAM) |
| PH (1) | PH12016502482A1 (OSRAM) |
| RU (1) | RU2698654C2 (OSRAM) |
| WO (1) | WO2015189832A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| KR20240132521A (ko) * | 2015-03-13 | 2024-09-03 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| JP7097433B2 (ja) * | 2017-08-17 | 2022-07-07 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法 |
| US20210130396A1 (en) * | 2017-08-30 | 2021-05-06 | Ares Trading S.A. | Method for purifying proteins |
| US11952399B2 (en) * | 2018-12-18 | 2024-04-09 | Amgen Inc. | Methods for purifying proteins |
| AU2020216368B2 (en) * | 2019-01-30 | 2025-04-24 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| US20230357315A1 (en) * | 2020-03-11 | 2023-11-09 | Dr. Reddy's Laboratories Limited | METHOD OF PURIFYING AN Fc-FUSION PROTEIN |
| CN113563469A (zh) * | 2020-04-28 | 2021-10-29 | 江苏中新医药有限公司 | 高回收率纯化阿达木单抗的方法 |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| AU2022357575A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process for purification of protein |
| WO2023053032A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of fusion protein |
| WO2023053031A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| CA3235508A1 (en) * | 2021-10-19 | 2023-05-11 | Soon Jae Park | Method for purifying fusion protein having igg fc domain |
| JPWO2023095665A1 (OSRAM) * | 2021-11-29 | 2023-06-01 | ||
| CN119060168A (zh) * | 2024-09-26 | 2024-12-03 | 广东丸美生物技术股份有限公司 | 一种具有低电导率的重组胶原蛋白溶液及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021284C1 (ru) * | 1991-05-30 | 1994-10-15 | Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов | Способ очистки клинических фракций декстрана |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| PT1601697E (pt) | 2003-02-28 | 2007-09-04 | Lonza Biologics Plc | Purificação de anticorpos através de proteína a e cromatografia de troca iónica. |
| US8263750B2 (en) * | 2006-03-16 | 2012-09-11 | Amgen Inc. | Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step |
| JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| WO2008025748A1 (en) * | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
| CA2701221A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an fc-containing protein |
| CN102239177A (zh) * | 2008-02-29 | 2011-11-09 | 比奥根艾迪克Ma公司 | 纯化的免疫球蛋白融合蛋白及其纯化方法 |
| CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| KR101753569B1 (ko) * | 2010-01-22 | 2017-07-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법 |
| WO2012176158A1 (en) * | 2011-06-24 | 2012-12-27 | Dr. Reddy's Laboratories Limited | Purification of chimeric protein |
| CA2840951A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Methods for purifying fc-fusion protein |
| KR101454316B1 (ko) * | 2011-08-17 | 2014-10-27 | 한화케미칼 주식회사 | 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법 |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| WO2014043103A1 (en) * | 2012-09-11 | 2014-03-20 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
| CN102911250B (zh) * | 2012-09-29 | 2014-04-16 | 浙江海正药业股份有限公司 | 酸性重组蛋白药物的纯化方法 |
| WO2014078627A1 (en) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | Liquid formulations for tnfr:fc fusion proteins |
| HUE038565T2 (hu) * | 2013-03-14 | 2018-10-29 | Amgen Inc | Kiszivárgott affinitás tisztító ligandumok eltávolítása |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
-
2015
- 2015-06-13 WO PCT/IB2015/054494 patent/WO2015189832A1/en not_active Ceased
- 2015-06-13 CN CN201580038801.XA patent/CN106536565A/zh active Pending
- 2015-06-13 CA CA2951766A patent/CA2951766A1/en not_active Abandoned
- 2015-06-13 EP EP15734731.1A patent/EP3155009A1/en not_active Withdrawn
- 2015-06-13 JP JP2016572703A patent/JP6747985B2/ja not_active Expired - Fee Related
- 2015-06-13 US US15/318,489 patent/US10556942B2/en active Active
- 2015-06-13 MX MX2016016318A patent/MX2016016318A/es unknown
- 2015-06-13 AU AU2015273049A patent/AU2015273049B2/en not_active Ceased
- 2015-06-13 BR BR112016029157A patent/BR112016029157A8/pt not_active Application Discontinuation
- 2015-06-13 MA MA040232A patent/MA40232A/fr unknown
- 2015-06-13 RU RU2017100005A patent/RU2698654C2/ru active
-
2016
- 2016-12-13 PH PH12016502482A patent/PH12016502482A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016029157A2 (pt) | 2017-08-22 |
| WO2015189832A1 (en) | 2015-12-17 |
| US10556942B2 (en) | 2020-02-11 |
| RU2017100005A (ru) | 2018-07-13 |
| JP2017521389A (ja) | 2017-08-03 |
| AU2015273049B2 (en) | 2019-11-14 |
| MX2016016318A (es) | 2017-06-12 |
| CA2951766A1 (en) | 2015-12-17 |
| EP3155009A1 (en) | 2017-04-19 |
| RU2017100005A3 (OSRAM) | 2019-02-28 |
| US20170152298A1 (en) | 2017-06-01 |
| AU2015273049A1 (en) | 2017-01-12 |
| PH12016502482A1 (en) | 2017-04-10 |
| CN106536565A (zh) | 2017-03-22 |
| RU2698654C2 (ru) | 2019-08-28 |
| BR112016029157A8 (pt) | 2021-07-06 |
| MA40232A (fr) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6747985B2 (ja) | ＴＮＦＲ：Ｆｃ融合タンパク質の精製方法 | |
| KR101683415B1 (ko) | 단일클론항체에 대한 정제 방법 | |
| CN102712673B (zh) | 用于纯化含fc的蛋白的色谱方法 | |
| US20140288278A1 (en) | Chromatography process for resolving heterogeneous antibody aggregates | |
| RU2590726C2 (ru) | Способ очистки витамин к-зависимых белков, таких как коагуляционный фактор ix | |
| JP6151640B2 (ja) | たん白質の精製方法 | |
| US20030166869A1 (en) | Methods for purifying protein | |
| CN113710685B (zh) | 通过使用捕获前的絮凝改善免疫球蛋白的亲和色谱 | |
| EP2695889A1 (en) | Protein purification by ion exchange | |
| KR20110139216A (ko) | 소형 모듈형 면역약제 단백질의 정제 방법 | |
| NZ574623A (en) | Process for the purification of fc-fusion proteins | |
| CN105121469A (zh) | 用于增加蛋白质的焦谷氨酸形成的方法 | |
| JP7458980B2 (ja) | アルキルグリコシドによるタンパク質精製およびウイルス不活化 | |
| CN105777904A (zh) | 抗TNFα类单克隆抗体的阳离子交换色谱纯化方法 | |
| CN102911250B (zh) | 酸性重组蛋白药物的纯化方法 | |
| JP2023523823A (ja) | タンパク質の精製の改善されたプロセス | |
| JP2023139142A (ja) | 眼科用タンパク質医薬品の精製方法（Ｒｅｆｉｎｉｎｇ ｍｅｔｈｏｄ ｏｆ ｏｐｈｔｈａｌｍｉｃ ｐｒｏｔｅｉｎ ｐｈａｒｍａｃｅｕｔｉｃａｌｓ） | |
| CN111849945A (zh) | 人凝血因子VIIa的纯化方法 | |
| CN109929038B (zh) | Vegf捕获剂融合蛋白的纯化方法 | |
| CN106148302A (zh) | 一种重组蛋白质的纯化方法 | |
| CN105777903B (zh) | 一种阿达木单抗的阳离子交换色谱纯化方法 | |
| KR20070091098A (ko) | 단백질 분리 방법 | |
| Yoshimoto et al. | Large scale purification of isoinhibitors of trypsin from swine colostrum using zinc chelate chromatography and chromatofocusing | |
| WO2025219869A1 (en) | Methods of purifying immunoglobulins comprising n-terminal glutamine | |
| CN118291432A (zh) | 一种利用非亲和层析捕获技术纯化蛋白的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170511 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20170621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180605 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200410 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200806 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6747985 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |